Preoperative Erector Spinae Plane Block Versus Paravertebral Plane Block in Decreasing Post Mastectomy Pain Syndrome

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-60
SponsorNational Cancer Institute, Egypt

About this trial

Breast cancer is considered the commonest malignancy affecting women with an incidence exceeding one million cases per year. Although it has a favorable prognosis with improved lines of treatment, some complications may still disturb the patient's life quality. One of these complications is post-mastectomy pain syndrome (PMPS) .Regional Anaesthesia (RA) is considered one of the most effective methods in reducing acute pain after breast surgeries, these include pectoral nerves block (PECS), serratus anterior plane block (SAPB), paravertebral plane block (PVPB) and erector spinae plane block (ESPB) . Our study is aiming for comparing the effect of preoperative PVPB versus preoperative ESPB in the prevention of PMPS in patients undergoing unilateral breast surgeries.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age ≥ 18 years and ≤ 60 years old.

Female patients ASA ΙΙ, ΙΙΙ.

Female patients scheduled for unilateral breast surgeries.

Disqualifiers

Patient refusal.

Patients have sepsis

Patients known to have allergy against local anesthetics.

Patients with prior surgery in areas above or below the clavicle or in the axillary region.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Paravertebral plane block

    Procedure/Surgery

    With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the transverse processes clearly visualized . Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique toward the paravertebral space, immediately above the pleura and below the superior costotransverse ligament. The position of the needle is confirmed by the descent of the pleura when injecting 2 to 3 ml of saline solution for hydrolocalization. Then 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.

  • Erector spinae plane block

    Procedure/Surgery

    With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the tips of the transverse processes clearly visualized . The following muscles seen from superficial to deep layer are trapezius, rhomboid major and erector spinae muscles. Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique to reach the interfascial plane between the transverse process and the erector spinae muscle. Following confirmation of the accurate position of the needle tip with 3-5 ml normal saline solution, 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.

  • Intravenous morphine, ketorlac and paracetamol

    Drug

    • In the control group only we add 10mg intravenous morphine, 30 mg intravenous ketorlac and 1 gm intravenous paracetamol for analgesia.

Treatment groups

51 Participants
are divided into 3 treatment groups
Group A: Paravertebral Block GroupActive comparator 1 intervention
Group B: Erector Spinae Block GroupActive comparator 1 intervention
Group C: Control GroupOther 1 intervention

Trial outcomes

Primary outcomes

1

The primary outcome is to assess the incidence of PMPS 3 months after surgery.

* A junior pain physician is blinded to all treatment groups and asks about symptoms of PMPS including (pain, tingling, numbness, shooting pain, pricking pain or unbearable itching), site (chest wall, armpit, arm, shoulder or surgical scar) and grading scale using the brief pain inventory (BPI). * Chronic pain is defined by a score of ≥ 3 on the single item (average pain) of the BPI. * The BPI consists of three domains: (1) Pain intensity measured using the visual analogue scale (VAS) of 0 (no pain) to 10 (worst pain). (2) Pain that interferes with daily activities measured using a scale of 0 (no interference) to 10 (complete restriction to daily activities). (3) Percentage of relief provided by pain treatments measured using a scale of 0 (complete relief) to 10 (no relief) by the NRS.

Time frame
3 months

Secondary outcomes

1

• The prevalence of PMPS at 6 months.

• The prevalence of PMPS at 6 months.

Time frame
6 months
2

• Assessment of acute postoperative pain.

• Assessment of acute postoperative pain using VAS (0 for no pain, 10 for the worst pain) at 0, 4, 8, 24 and 48 hours postoperatively.

Time frame
48 hours
3

• Time to first needed morphine dose postoperatively, total 24-48 hours morphine consumption.

• Time to first needed morphine dose postoperatively, total 24-48 hours morphine consumption.

Time frame
48 hours .
4

• PVPB and ESPB related complications.

• PVPB and ESPB related complications (bupivacaine toxicity, pneumothorax).

Time frame
24 hours

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: